Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage
Hoth Therapeutics (NASDAQ: HOTH) has received a USPTO Filing Receipt for a new patent application covering the proprietary formulation of HT-001, its lead clinical asset. This application aims to expand the company's intellectual property portfolio, building upon their existing approved patent for the compound.
The formulation-specific filing focuses on protecting the unique composition and delivery method of HT-001, which is being developed as a topical treatment for dermatologic side effects in cancer patients undergoing EGFR inhibitor therapy. The USPTO Filing Receipt confirms the patent application's formal acceptance for examination, strengthening Hoth's IP position as they advance HT-001 through clinical development.
Hoth Therapeutics (NASDAQ: HOTH) ha ricevuto una Ricevuta di Deposito USPTO per una nuova domanda di brevetto che copre la formulazione proprietaria di HT-001, il suo principale asset clinico. Questa domanda mira ad ampliare il portafoglio di proprietà intellettuale dell'azienda, basandosi sul loro brevetto già approvato per il composto.
Il deposito specifico della formulazione si concentra sulla protezione della composizione unica e del metodo di somministrazione di HT-001, che è in fase di sviluppo come trattamento topico per gli effetti collaterali dermatologici nei pazienti oncologici sottoposti a terapia con inibitori dell'EGFR. La Ricevuta di Deposito USPTO conferma l'accettazione formale della domanda di brevetto per l'esame, rafforzando la posizione di proprietà intellettuale di Hoth mentre avanzano con HT-001 nello sviluppo clinico.
Hoth Therapeutics (NASDAQ: HOTH) ha recibido un Recibo de Presentación de la USPTO para una nueva solicitud de patente que cubre la formulación propietaria de HT-001, su principal activo clínico. Esta solicitud tiene como objetivo ampliar el portafolio de propiedad intelectual de la empresa, basándose en su patente aprobada existente para el compuesto.
El depósito específico de la formulación se centra en proteger la composición única y el método de entrega de HT-001, que se está desarrollando como un tratamiento tópico para los efectos secundarios dermatológicos en pacientes con cáncer que reciben terapia con inhibidores de EGFR. El Recibo de Presentación de la USPTO confirma la aceptación formal de la solicitud de patente para su examen, fortaleciendo la posición de propiedad intelectual de Hoth a medida que avanzan con HT-001 en el desarrollo clínico.
Hoth Therapeutics (NASDAQ: HOTH)는 HT-001의 독점 제형을 다루는 새로운 특허 신청서에 대한 USPTO 제출 영수증을 받았습니다. 이 신청서는 회사의 지적 재산 포트폴리오를 확장하는 것을 목표로 하며, 기존의 승인된 화합물 특허를 기반으로 하고 있습니다.
제형별 제출은 HT-001의 독특한 조성과 전달 방법을 보호하는 데 중점을 두고 있으며, 이는 EGFR 억제제 치료를 받고 있는 암 환자의 피부과적 부작용을 위한 국소 치료제로 개발되고 있습니다. USPTO 제출 영수증은 특허 신청서가 심사를 위한 공식 수락을 확인하며, Hoth가 HT-001을 임상 개발로 진행하는 데 있어 지적 재산 위치를 강화합니다.
Hoth Therapeutics (NASDAQ: HOTH) a reçu un Reçu de Dépôt de l'USPTO pour une nouvelle demande de brevet couvrant la formulation propriétaire de HT-001, son principal actif clinique. Cette demande vise à élargir le portefeuille de propriété intellectuelle de l'entreprise, en s'appuyant sur leur brevet déjà approuvé pour le composé.
Le dépôt spécifique à la formulation se concentre sur la protection de la composition unique et de la méthode de livraison de HT-001, qui est en cours de développement en tant que traitement topique pour les effets secondaires dermatologiques chez les patients atteints de cancer recevant une thérapie par inhibiteurs de l'EGFR. Le Reçu de Dépôt de l'USPTO confirme l'acceptation formelle de la demande de brevet pour examen, renforçant la position de propriété intellectuelle de Hoth alors qu'ils avancent avec HT-001 dans le développement clinique.
Hoth Therapeutics (NASDAQ: HOTH) hat eine USPTO-Eingangsbestätigung für einen neuen Patentantrag erhalten, der die proprietäre Formulierung von HT-001, ihrem führenden klinischen Asset, abdeckt. Dieser Antrag zielt darauf ab, das geistige Eigentumsportfolio des Unternehmens zu erweitern, basierend auf ihrem bereits genehmigten Patent für die Verbindung.
Der formulierungsspezifische Antrag konzentriert sich darauf, die einzigartige Zusammensetzung und die Verabreichungsmethode von HT-001 zu schützen, das als topische Behandlung für dermatologische Nebenwirkungen bei Krebspatienten entwickelt wird, die sich einer EGFR-Inhibitor-Therapie unterziehen. Die USPTO-Eingangsbestätigung bestätigt die formale Annahme des Patentantrags zur Prüfung und stärkt die IP-Position von Hoth, während sie HT-001 durch die klinische Entwicklung vorantreiben.
- Received USPTO Filing Receipt for new HT-001 formulation patent application
- Expands IP protection beyond existing approved patent
- Strengthens intellectual property position for lead clinical asset
- None.
This newly filed application seeks to expand the Company's intellectual property portfolio surrounding HT-001 and builds upon Hoth's already approved patent for the compound. The formulation-specific filing is aimed at further protecting the unique composition and delivery method of HT-001, which is being developed as a novel topical treatment to alleviate dermatologic side effects commonly experienced by cancer patients undergoing epidermal growth factor receptor (EGFR) inhibitor therapy.
"The receipt of this Filing Receipt from the USPTO marks another critical milestone in the development of HT-001," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "Expanding our patent protection to include formulation-specific claims reinforces the strength of our IP position and our long-term commitment to patients and shareholders."
The USPTO Filing Receipt confirms that the patent application has been formally accepted and will proceed through the examination process. This development adds an important layer of protection as Hoth continues advancing HT-001 through clinical development.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-receives-uspto-filing-receipt-for-ht-001-formulation-patent-application-expanding-existing-patent-coverage-302416196.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What is the purpose of Hoth Therapeutics' new patent application for HT-001?
How does the USPTO Filing Receipt impact HOTH's intellectual property portfolio?
What medical condition does Hoth Therapeutics' HT-001 target?
What stage of development is HOTH's HT-001 currently in?
